![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Departments of Pharmacokinetics Dynamics & Metabolism (S.J.R., S.C., D.G., S.G.J., A.N.R.N., D.A.S., D.K.), Drug Safety Evaluation (P.C.), and Clinical Sciences (N.W.), Pfizer Global Research and Development, Sandwich, Kent, United Kingdom
Voriconazole is a new triazole antifungal agent with potent, wide-spectrum activity. Its pharmacokinetics and metabolism have been studied in mouse, rat, rabbit, dog, guinea pig, and humans after single and multiple administration by both oral and intravenous routes. Absorption of voriconazole is essentially complete in all species. The elimination of voriconazole is characterized by non-linear pharmacokinetics in all species. Consequently, pharmacokinetic parameters are dependent upon dose, and a superproportional increase in area under the curve is seen with increasing dose in rat and dog toxicology studies. Following multiple administration, there is a decrease in systemic exposure. This is most pronounced in mouse and rat, less so in dog, and not observed in guinea pig or rabbit. Repeat-dose toxicology studies in mouse, rat, and dog have demonstrated that induction of cytochrome P450 by voriconazole (autoinduction of metabolism) is responsible for the decreased exposure in these species. Autoinduction of metabolism is not observed in humans, and plasma steady-state concentrations remain constant with time. Voriconazole is extensively metabolized in all species. The major pathways in humans involve fluoropyrimidine N-oxidation, fluoropyrimidine hydroxylation, and methyl hydroxylation. Also, N-oxidation facilitates cleavage of the molecule, resulting in loss of the fluoropyrimidine moiety and subsequent conjugation with glucuronic acid. Major pathways are represented in animal species. The major circulating metabolite in rat, dog, and human is the N-oxide of voriconazole. It is not thought to contribute to efficacy since it is at least 100-fold less potent than voriconazole against fungal pathogens in vitro.
This article has been cited by other articles:
|
|
 |
|
  M. Marine, F. J. Pastor, C. Serena, and J. Guarro Efficacy of Triazoles in a Murine Disseminated Infection by Candida krusei Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3585 - 3588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Joukhadar, C. Thallinger, W. Poppl, F. Kovar, K. H. Konz, S. M. Joukhadar, and F. Traunmuller Concentrations of Voriconazole in Healthy and Inflamed Lung in Rats Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2684 - 2686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. J. van de Sande, R. A. A. Mathot, M. T. ten Kate, W. van Vianen, M. Tavakol, B. J. A. Rijnders, and I. A. J. M. Bakker-Woudenberg Combination Therapy of Advanced Invasive Pulmonary Aspergillosis in Transiently Neutropenic Rats Using Human Pharmacokinetic Equivalent Doses of Voriconazole and Anidulafungin Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2005 - 2013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Moriyama, J. Elinoff, R. L. Danner, J. Gea-Banacloche, G. Pennick, M. G. Rinaldi, and T. J. Walsh Accelerated Metabolism of Voriconazole and Its Partial Reversal by Cimetidine Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1712 - 1714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jeong, P. D. Nguyen, and Z. Desta Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A Antimicrob. Agents Chemother., February 1, 2009; 53(2): 541 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Weiss, M. M. ten Hoevel, J. Burhenne, I. Walter-Sack, M. M. Hoffmann, J. Rengelshausen, W. E. Haefeli, and G. Mikus CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole J. Clin. Pharmacol., February 1, 2009; 49(2): 196 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Arendrup, S. Perkhofer, S. J. Howard, G. Garcia-Effron, A. Vishukumar, D. Perlin, and C. Lass-Florl Establishing In Vitro-In Vivo Correlations for Aspergillus fumigatus: the Challenge of Azoles versus Echinocandins Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3504 - 3511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Vallor, W. R. Kirkpatrick, L. K. Najvar, R. Bocanegra, M. C. Kinney, A. W. Fothergill, M. L. Herrera, B. L. Wickes, J. R. Graybill, and T. F. Patterson Assessment of Aspergillus fumigatus Burden in Pulmonary Tissue of Guinea Pigs by Quantitative PCR, Galactomannan Enzyme Immunoassay, and Quantitative Culture Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2593 - 2598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Yanni, P. P. Annaert, P. Augustijns, A. Bridges, Y. Gao, D. K. Benjamin Jr., and D. R. Thakker Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver Microsomes Drug Metab. Dispos., June 1, 2008; 36(6): 1119 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Troke, K. Aguirrebengoa, C. Arteaga, D. Ellis, C. H. Heath, I. Lutsar, M. Rovira, Q. Nguyen, M. Slavin, S. C. A. Chen, et al. Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1743 - 1750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Saunte, F. Simmel, N. Frimodt-Moller, L. B. Stolle, E. L. Svejgaard, M. Haedersdal, C. Kloft, and M. C. Arendrup In Vivo Efficacy and Pharmacokinetics of Voriconazole in an Animal Model of Dermatophytosis Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3317 - 3321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Weiler, H. Zoller, I. Graziadei, W. Vogel, R. Bellmann-Weiler, M. Joannidis, and R. Bellmann Altered Pharmacokinetics of Voriconazole in a Patient with Liver Cirrhosis Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3459 - 3460. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Serena, F. J. Pastor, M. Marine, M. M. Rodriguez, and J. Guarro Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection J. Antimicrob. Chemother., July 1, 2007; 60(1): 162 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pascual, V. Nieth, T. Calandra, J. Bille, S. Bolay, L. A. Decosterd, T. Buclin, P. A. Majcherczyk, D. Sanglard, and O. Marchetti Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods Antimicrob. Agents Chemother., January 1, 2007; 51(1): 137 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hummel, B. Spiess, K. Kentouche, S. Niggemann, C. Bohm, S. Reuter, M. Kiehl, H. Morz, R. Hehlmann, and D. Buchheidt Detection of Aspergillus DNA in Cerebrospinal Fluid from Patients with Cerebral Aspergillosis by a Nested PCR Assay J. Clin. Microbiol., November 1, 2006; 44(11): 3989 - 3993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Serena, F. Gilgado, M. Marine, F. J. Pastor, and J. Guarro Efficacy of voriconazole in a Guinea pig model of invasive trichosporonosis. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2240 - 2243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Capitano, B. A. Potoski, S. Husain, S. Zhang, D. L. Paterson, S. M. Studer, K. R. McCurry, and R. Venkataramanan Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1878 - 1880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Dowell, J. Schranz, A. Baruch, and G. Foster Safety and Pharmacokinetics of Coadministered Voriconazole and Anidulafungin J. Clin. Pharmacol., December 1, 2005; 45(12): 1373 - 1382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. MacCallum, J. A. Whyte, and F. C. Odds Efficacy of Caspofungin and Voriconazole Combinations in Experimental Aspergillosis Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3697 - 3701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Novotny What Can Pharmacokinetic Models Tell Us about the Disposition of Lycopene and the Potential Role of Lycopene in Cancer Prevention? J. Nutr., August 1, 2005; 135(8): 2048S - 2049S. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Singh and D. L. Paterson Aspergillus Infections in Transplant Recipients Clin. Microbiol. Rev., January 1, 2005; 18(1): 44 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Harrison, A. Betts, K. Fenner, K. Beaumont, A. Edgington, S. Roffey, J. Davis, P. Comby, and P. Morgan NONLINEAR ORAL PHARMACOKINETICS OF THE {alpha}-ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS Drug Metab. Dispos., February 1, 2004; 32(2): 197 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Groll, H. Kolve, K. Ehlert, M. Paulussen, and J. Vormoor Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation J. Antimicrob. Chemother., January 1, 2004; 53(1): 113 - 114. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
